var data={"title":"Paraneoplastic visual syndromes","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Paraneoplastic visual syndromes</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/contributors\" class=\"contributor contributor_credentials\">Josep Dalmau, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/contributors\" class=\"contributor contributor_credentials\">Myrna R Rosenfeld, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/contributors\" class=\"contributor contributor_credentials\">Lisa M DeAngelis, MD, FAAN, FANA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/contributors\" class=\"contributor contributor_credentials\">April F Eichler, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 11, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H2791602\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Paraneoplastic neurologic syndromes are a heterogeneous group of neurologic disorders associated with systemic cancer and caused by mechanisms other than metastases, metabolic and nutritional deficits, infections, coagulopathy, or side effects of cancer treatment. In most cases, their pathogenesis is believed to be immune-mediated.</p><p>Paraneoplastic visual syndromes are rare; they include cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR), paraneoplastic optic neuropathy (optic neuritis), and bilateral diffuse uveal melanocytic proliferation.</p><p>This topic discusses paraneoplastic visual syndromes. An overview of paraneoplastic syndromes and other paraneoplastic disorders are discussed separately. (See <a href=\"topic.htm?path=overview-of-paraneoplastic-syndromes-of-the-nervous-system\" class=\"medical medical_review\">&quot;Overview of paraneoplastic syndromes of the nervous system&quot;</a> and <a href=\"topic.htm?path=paraneoplastic-syndromes-affecting-peripheral-nerve-and-muscle\" class=\"medical medical_review\">&quot;Paraneoplastic syndromes affecting peripheral nerve and muscle&quot;</a> and <a href=\"topic.htm?path=paraneoplastic-syndromes-affecting-the-spinal-cord-and-dorsal-root-ganglia\" class=\"medical medical_review\">&quot;Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia&quot;</a> and <a href=\"topic.htm?path=paraneoplastic-and-autoimmune-encephalitis\" class=\"medical medical_review\">&quot;Paraneoplastic and autoimmune encephalitis&quot;</a> and <a href=\"topic.htm?path=paraneoplastic-cerebellar-degeneration\" class=\"medical medical_review\">&quot;Paraneoplastic cerebellar degeneration&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2792544\"><span class=\"h1\">CANCER-ASSOCIATED RETINOPATHY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cancer-associated retinopathy (CAR), while rare, is probably the most common of the paraneoplastic visual syndromes. The pathogenesis of CAR is believed to be a B-cell mediated autoimmune response directed against an antigen expressed by both tumor and retina [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/1\" class=\"abstract_t\">1</a>]. T-cell responses may also play a role.</p><p>Although at least 20 antigens have been described in the CAR syndrome, the first described was recoverin, a calcium-binding protein involved in transduction of light by photoreceptors (<a href=\"image.htm?imageKey=ONC%2F67930\" class=\"graphic graphic_picture graphicRef67930 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/2-4\" class=\"abstract_t\">2-4</a>]. Recoverin is expressed in the tumors of patients with lung cancer with or without CAR; antibodies to CAR may occur in patients without visual symptoms, although the titres are relatively low compared with patients with visual loss [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/4,5\" class=\"abstract_t\">4,5</a>]. Anti-recoverin antibodies have been shown to induce apoptotic death of photoreceptor cells in vitro [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/6\" class=\"abstract_t\">6</a>]. Anti-enolase antibodies are associated with a less severe retinopathy that affects mainly the cones; not all patients with anti-enolase associated retinopathy have cancer [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/7-10\" class=\"abstract_t\">7-10</a>]. Other antigens have been identified in patients with CAR; about 35 percent of patients with CAR are seronegative suggesting that other antigens remain to be characterized [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/11,12\" class=\"abstract_t\">11,12</a>].</p><p>Histopathology reveals diffuse loss of inner and outer segments of the photoreceptors and loss of the outer nuclear layer with preservation of the inner nuclear layer [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/13\" class=\"abstract_t\">13</a>]. Inflammation is variably observed.</p><p>Patients with CAR develop symptoms related to dysfunction of both cones (ie, photosensitivity, abnormal visual acuity, color vision abnormalities, central scotomata) and rods (ie, nyctalopia or night blindness, prolonged dark adaptation, peripheral or ring-like scotomata). Patients typically describe photopsias along with bilateral visual dimming that progresses over days to weeks. The triad of photosensitivity, ring scotomatous visual field loss, and attenuated retinal arteriole caliber is strongly suggestive of this disorder, although the optic fundus can appear normal in the early stages [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/14\" class=\"abstract_t\">14</a>]. Optic disc pallor and mottling of the epithelium develop in later stages [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/15\" class=\"abstract_t\">15</a>].</p><p>Electroretinogram (ERG) is abnormal, with depressed a and b-waves in both photopic and scotopic conditions, reflecting damage to both rods and cones. Cerebrospinal fluid analysis may be normal or show mild lymphocytic pleocytosis <span class=\"nowrap\">and/or</span> elevated protein.</p><p>The most commonly associated tumors are small cell lung cancer, breast cancer, gynecologic cancers, and hematological malignancies. Less frequently, hepatocellular carcinoma, colon cancer, prostate cancer, and thymoma have been reported [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/12,15-20\" class=\"abstract_t\">12,15-20</a>]. CAR precedes cancer diagnosis in approximately half of patients.</p><p>Patients with unexplained vision loss with clinical or electrophysiologic evidence of rod and cone dysfunction or known or suspected malignancy should be evaluated for CAR. Testing should include measurement of anti-retinal antibodies along with investigation for underlying neoplasm (see <a href=\"topic.htm?path=overview-of-paraneoplastic-syndromes-of-the-nervous-system#H13\" class=\"medical medical_review\">&quot;Overview of paraneoplastic syndromes of the nervous system&quot;, section on 'Occult malignancy'</a>). Negative antibody titres on initial examination, can become positive on subsequent testing [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/21\" class=\"abstract_t\">21</a>]. The specificity of anti-recoverin antibodies for underlying neoplasm in patients with retinopathy appears to be high; in one series, all 12 patients with retinopathy and anti-recoverin antibodies had cancer [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/22\" class=\"abstract_t\">22</a>]. In another series of 521 patients with a diagnosis of retinitis pigmentosa, ten patients had antirecoverin antibody <span class=\"nowrap\">and/or</span> cellular immunoreactivity; none of these patients appeared to have systemic malignancy [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/23\" class=\"abstract_t\">23</a>]. Anti-enolase and other antibodies are not specific for CAR and may be seen in patients with noncancer-related autoimmune retinopathy [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/22\" class=\"abstract_t\">22</a>].</p><p>Traditionally, CAR has been treated with corticosteroids with anecdotal reports of mild to moderate improvement that was rarely sustained [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/15,24\" class=\"abstract_t\">15,24</a>]. Treatment of the underlying tumor also does not clearly affect visual prognosis. There are anecdotal, uncontrolled reports of a treatment response to intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/25\" class=\"abstract_t\">25</a>], plasmapheresis [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/26\" class=\"abstract_t\">26</a>], <a href=\"topic.htm?path=alemtuzumab-drug-information\" class=\"drug drug_general\">alemtuzumab</a> [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/19\" class=\"abstract_t\">19</a>], and <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/27\" class=\"abstract_t\">27</a>]. For most patients, however, the visual prognosis is poor with progressive visual loss and eventual blindness [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H2792551\"><span class=\"h1\">MELANOMA-ASSOCIATED RETINOPATHY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The sera of patients with melanoma-associated retinopathy (MAR) contain antibodies that react with the bipolar cells of the retina [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/29-31\" class=\"abstract_t\">29-31</a>]. Potential antigens (eg, arrestin, transducin) have been identified [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/32-34\" class=\"abstract_t\">32-34</a>]. Anti-retinal antibodies are also prevalent (in as many as 69 percent) in patients with melanoma but no retinopathy [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/35\" class=\"abstract_t\">35</a>]. In one series, 9 of 11 patients with MAR had a family or personal history of autoimmune disease [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/36\" class=\"abstract_t\">36</a>].</p><p>Clinical features of melanoma-associated retinopathy (MAR) include shimmering, flickering, or pulsating photopsias, night blindness, and loss of peripheral vision [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/29,36-38\" class=\"abstract_t\">29,36-38</a>]. Color vision is preserved. The onset is usually acute and may begin in one eye. Vision loss progresses slowly; in one series, visual acuity was <span class=\"nowrap\">20/60</span> or better in more than 80 percent of patients at diagnosis [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/38\" class=\"abstract_t\">38</a>].</p><p>Funduscopic examination is usually normal at onset, with retinal arterial attenuation seen later [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/13,38\" class=\"abstract_t\">13,38</a>]. Vitreous cells are seen in a few patients. The electroretinogram shows a characteristic pattern of a markedly reduced b-wave in the presence of a normal, dark-adapted a-wave, consistent with bipolar and Muller cell dysfunction. Cerebrospinal fluid analysis is generally normal.</p><p>MAR usually presents in the setting of known melanoma, sometimes after an interval of months to years [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/38\" class=\"abstract_t\">38</a>]. MAR may precede the diagnosis of melanoma. Patients with any form of melanoma (cutaneous, choroidal, ciliary body, or choroidal nevi) may be affected, usually in the context of metastatic disease [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/29,36\" class=\"abstract_t\">29,36</a>]. A few patients with a MAR-like illness have been reported in patients with colon cancer [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/16\" class=\"abstract_t\">16</a>].</p><p>The diagnosis of MAR is usually made in the setting of a typical clinical presentation in a patient with melanoma. Western blot and immunohistologic examination can demonstrate anti-retinal antibodies but this has imperfect sensitivity and specificity [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/36\" class=\"abstract_t\">36</a>].</p><p>Vision loss typically stabilizes or progresses slowly. Some patients, but not most, improve with treatment of the tumor, <span class=\"nowrap\">and/or</span> with immunotherapy: glucocorticoids, plasma exchange, <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, or intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> (IVIG) (eg, 0.4 <span class=\"nowrap\">g/kg</span> daily for five days) [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/12,15,28,38-40\" class=\"abstract_t\">12,15,28,38-40</a>]; there are no controlled studies. Some believe that MAR is associated with prolonged survival from melanoma, but this has not been rigorously assessed [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/41\" class=\"abstract_t\">41</a>].</p><p class=\"headingAnchor\" id=\"H2791281\"><span class=\"h1\">OPTIC NEUROPATHY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Paraneoplastic optic neuritis (PON) has been described in a few reports, usually in association with other paraneoplastic neurologic syndromes, in particular encephalomyelitis or retinitis [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/42-46\" class=\"abstract_t\">42-46</a>]. Many of these patients harbor antibodies to the 62kDa collapsin-responsive mediator protein-5 (CRMP-5, also called anti-CV2) [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/43-45,47\" class=\"abstract_t\">43-45,47</a>]. However, the small number of patients, the extensive number of accompanying symptoms, and the frequent co-occurrence of other antibodies suggest low specificity and sensitivity of CRMP-5 antibodies as markers of paraneoplastic optic neuritis or retinitis associated with SCLC [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/44\" class=\"abstract_t\">44</a>].</p><p>Patients typically present with painless visual loss and optic disc edema [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/13,44,48\" class=\"abstract_t\">13,44,48</a>]. Both eyes are usually ultimately involved. Magnetic resonance imaging (MRI) reveals a swollen optic nerve that may mildly enhance. <a href=\"topic.htm?path=fluorescein-drug-information\" class=\"drug drug_general\">Fluorescein</a> angiography can show optic disc hyperfluorescence and leakage. Vitreous cells may be prominent. Cerebrospinal fluid may reveal a mild lymphocytic pleocytosis <span class=\"nowrap\">and/or</span> a mildly elevated protein. Neuropathologic findings are consistent with optic neuritis including perivascular lymphocytic infiltration and demyelination [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/44,48\" class=\"abstract_t\">44,48</a>].</p><p>In addition to encephalomyelitis and retinitis, other associated paraneoplastic syndromes occurring with PON include cerebellar ataxia [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/44,47,49-51\" class=\"abstract_t\">44,47,49-51</a>], a Devic-like syndrome [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/44,45\" class=\"abstract_t\">44,45</a>], and ophthalmoplegia [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/42,52\" class=\"abstract_t\">42,52</a>]. Optic nerve dysfunction can precede, accompany, or occur after other neurologic symptoms. Some patients are described with isolated PON [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/44,48,53-56\" class=\"abstract_t\">44,48,53-56</a>].</p><p>PON usually occurs in the setting of known cancer, but occasionally is its first manifestation [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/15\" class=\"abstract_t\">15</a>]. Small cell lung cancer (SCLC) is the most commonly associated cancer, but PON along with anti CRMP-5 antibodies are described in non-small cell lung cancer [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/55,56\" class=\"abstract_t\">55,56</a>], breast cancer [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/53\" class=\"abstract_t\">53</a>], thymoma [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/45\" class=\"abstract_t\">45</a>], renal cancer [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/44\" class=\"abstract_t\">44</a>] and thyroid cancer [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/44\" class=\"abstract_t\">44</a>].</p><p>Vision may improve with anti-tumor treatment [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/15,28,47\" class=\"abstract_t\">15,28,47</a>]. In some reports, systemic corticosteroids are also associated with improvement, but this is not invariable; associated neurologic symptoms appear less likely to respond to treatment [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/28,46,54,55\" class=\"abstract_t\">28,46,54,55</a>]. One report describes visual improvement in two cases with intravitreal <a href=\"topic.htm?path=triamcinolone-drug-information\" class=\"drug drug_general\">triamcinolone</a> acetonide [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/53\" class=\"abstract_t\">53</a>].</p><p class=\"headingAnchor\" id=\"H4052000\"><span class=\"h1\">BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bilateral diffuse uveal melanocytic proliferation (BDUMP) describes a syndrome in which vision loss occurs along with diffuse bilateral proliferation of melanocytes in the uveal tract in patients with cancer. The mechanism is unknown, but does not appear to be mediated by autoimmunity.</p><p>Patients present with vision loss of varying severity [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/57-60\" class=\"abstract_t\">57-60</a>]. Visual symptoms often precede cancer diagnosis; associated malignancies include ovarian, uterine, lung, and pancreatic cancers. Funduscopic examination is often normal at first presentation, but later may reveal multiple, subtle, round or oval, red patches. <a href=\"topic.htm?path=fluorescein-drug-information\" class=\"drug drug_general\">Fluorescein</a> angiography reveals multifocal hyperfluorescence corresponding with these patches. Diffuse thickening of the uveal tract with elevated focal tumors may also be seen. Optical coherence tomography reveals loss of the retinal pigment epithelium [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/61-63\" class=\"abstract_t\">61-63</a>].</p><p>Bilateral retinal detachments and rapid cataract formation follow. Patients with BDUMP respond poorly if at all to surgical therapy, and most patients become blind. In limited reports, corticosteroid treatment did not appear to impact outcome [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/59,64\" class=\"abstract_t\">59,64</a>]. Patients with BDUMP treated with irradiation for presumed choroidal metastases had worsened vision [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/13\" class=\"abstract_t\">13</a>]. However, one case report describes improved vision in a women treated with external beam irradiation supplemented by drainage of subretinal fluid [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/60\" class=\"abstract_t\">60</a>].</p><p>A serum-bound protein that stimulates melanocytic proliferation in vitro (named melanocyte elongation and proliferation factor, CMEP factor) was found in two patients with BDUMP [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/65\" class=\"abstract_t\">65</a>]. Based on this finding, two patients were treated with plasmapheresis [<a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/66\" class=\"abstract_t\">66</a>]. One patient had CMEP factor prior to treatment, and the other was not tested. Both patients responded with stabilization of their visual examination.</p><p class=\"headingAnchor\" id=\"H2791288\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Paraneoplastic visual syndromes include cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR), paraneoplastic optic neuropathy, and bilateral diffuse uveal melanocytic proliferation.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with CAR develop photosensitivity, abnormal visual acuity, color vision abnormalities, and central or ring-like scotomata. Small cell lung cancer (SCLC) and gynecologic tumors are the most commonly associated tumors. (See <a href=\"#H2792544\" class=\"local\">'Cancer-associated retinopathy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical features of MAR include shimmering, flickering, or pulsating photopsias, night blindness, and loss of peripheral vision. MAR may precede the diagnosis of melanoma. (See <a href=\"#H2792551\" class=\"local\">'Melanoma-associated retinopathy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of CAR and MAR is usually ineffective, however, some patients improve with treatment of the tumor or immunotherapy. (See <a href=\"#H2792544\" class=\"local\">'Cancer-associated retinopathy'</a> above and <a href=\"#H2792551\" class=\"local\">'Melanoma-associated retinopathy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Paraneoplastic optic neuritis has been described in a few reports, usually in association with paraneoplastic encephalomyelitis or retinitis and SCLC. (See <a href=\"#H2791281\" class=\"local\">'Optic neuropathy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bilateral diffuse uveal melanocyte proliferation describes a rare paraneoplastic syndrome. This has a poor prognosis with bilateral retinal detachment and rapid cataract formation leading to blindness in many patients. Survival is shortened as well, with death resulting from complications of the underlying malignancy. (See <a href=\"#H4052000\" class=\"local\">'Bilateral diffuse uveal melanocytic proliferation'</a> above.)</p><p/><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/1\" class=\"nounderline abstract_t\">Ohguro H, Nakazawa M. Pathological roles of recoverin in cancer-associated retinopathy. Adv Exp Med Biol 2002; 514:109.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/2\" class=\"nounderline abstract_t\">Thirkill CE, FitzGerald P, Sergott RC, et al. Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. N Engl J Med 1989; 321:1589.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/3\" class=\"nounderline abstract_t\">Polans AS, Burton MD, Haley TL, et al. Recoverin, but not visinin, is an autoantigen in the human retina identified with a cancer-associated retinopathy. Invest Ophthalmol Vis Sci 1993; 34:81.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/4\" class=\"nounderline abstract_t\">Polans AS, Witkowska D, Haley TL, et al. Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci U S A 1995; 92:9176.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/5\" class=\"nounderline abstract_t\">Bazhin AV, Shifrina ON, Savchenko MS, et al. Low titre autoantibodies against recoverin in sera of patients with small cell lung cancer but without a loss of vision. Lung Cancer 2001; 34:99.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/6\" class=\"nounderline abstract_t\">Shiraga S, Adamus G. Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol 2002; 132:72.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/7\" class=\"nounderline abstract_t\">Weleber RG, Watzke RC, Shults WT, et al. Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies. Am J Ophthalmol 2005; 139:780.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/8\" class=\"nounderline abstract_t\">Adamus G, Aptsiauri N, Guy J, et al. The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. Clin Immunol Immunopathol 1996; 78:120.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/9\" class=\"nounderline abstract_t\">Dot C, Guigay J, Adamus G. Anti-alpha-enolase antibodies in cancer-associated retinopathy with small cell carcinoma of the lung. Am J Ophthalmol 2005; 139:746.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/10\" class=\"nounderline abstract_t\">Magrys A, Anekonda T, Ren G, Adamus G. The role of anti-alpha-enolase autoantibodies in pathogenicity of autoimmune-mediated retinopathy. J Clin Immunol 2007; 27:181.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/11\" class=\"nounderline abstract_t\">Eichen JG, Dalmau J, Demopoulos A, et al. The photoreceptor cell-specific nuclear receptor is an autoantigen of paraneoplastic retinopathy. J Neuroophthalmol 2001; 21:168.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/12\" class=\"nounderline abstract_t\">Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev 2009; 8:410.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/13\" class=\"nounderline abstract_t\">Ko MW, Dalmau J, Galetta SL. Neuro-ophthalmologic manifestations of paraneoplastic syndromes. J Neuroophthalmol 2008; 28:58.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/14\" class=\"nounderline abstract_t\">Jacobson DM, Thirkill CE, Tipping SJ. A clinical triad to diagnose paraneoplastic retinopathy. Ann Neurol 1990; 28:162.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/15\" class=\"nounderline abstract_t\">Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol 2003; 48:12.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/16\" class=\"nounderline abstract_t\">Jacobson DM, Adamus G. Retinal anti-bipolar cell antibodies in a patient with paraneoplastic retinopathy and colon carcinoma. Am J Ophthalmol 2001; 131:806.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/17\" class=\"nounderline abstract_t\">Katsuta H, Okada M, Nakauchi T, et al. Cancer-associated retinopathy associated with invasive thymoma. Am J Ophthalmol 2002; 134:383.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/18\" class=\"nounderline abstract_t\">Yamada G, Ohguro H, Aketa K, et al. Invasive thymoma with paraneoplastic retinopathy. Hum Pathol 2003; 34:717.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/19\" class=\"nounderline abstract_t\">Espandar L, O'Brien S, Thirkill C, et al. Successful treatment of cancer-associated retinopathy with alemtuzumab. J Neurooncol 2007; 83:295.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/20\" class=\"nounderline abstract_t\">Chang PY, Yang CH, Yang CM. Cancer-associated retinopathy in a patient with hepatocellular carcinoma: case report and literature review. Retina 2005; 25:1093.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/21\" class=\"nounderline abstract_t\">Ohguro H, Yokoi Y, Ohguro I, et al. Clinical and immunologic aspects of cancer-associated retinopathy. Am J Ophthalmol 2004; 137:1117.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/22\" class=\"nounderline abstract_t\">Adamus G, Ren G, Weleber RG. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol 2004; 4:5.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/23\" class=\"nounderline abstract_t\">Heckenlively JR, Fawzi AA, Oversier J, et al. Autoimmune retinopathy: patients with antirecoverin immunoreactivity and panretinal degeneration. Arch Ophthalmol 2000; 118:1525.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/24\" class=\"nounderline abstract_t\">Keltner JL, Thirkill CE, Tyler NK, Roth AM. Management and monitoring of cancer-associated retinopathy. Arch Ophthalmol 1992; 110:48.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/25\" class=\"nounderline abstract_t\">Guy J, Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol 1999; 117:471.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/26\" class=\"nounderline abstract_t\">Murphy MA, Thirkill CE, Hart WM Jr. Paraneoplastic retinopathy: a novel autoantibody reaction associated with small-cell lung carcinoma. J Neuroophthalmol 1997; 17:77.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/27\" class=\"nounderline abstract_t\">Mahdi N, Faia LJ, Goodwin J, et al. A case of autoimmune retinopathy associated with thyroid carcinoma. Ocul Immunol Inflamm 2010; 18:322.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/28\" class=\"nounderline abstract_t\">Damek DM. Paraneoplastic Retinopathy/Optic Neuropathy. Curr Treat Options Neurol 2005; 7:57.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/29\" class=\"nounderline abstract_t\">Boeck K, Hofmann S, Klopfer M, et al. Melanoma-associated paraneoplastic retinopathy: case report and review of the literature. Br J Dermatol 1997; 137:457.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/30\" class=\"nounderline abstract_t\">Milam AH, Saari JC, Jacobson SG, et al. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci 1993; 34:91.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/31\" class=\"nounderline abstract_t\">Potter MJ, Adamus G, Szabo SM, et al. Autoantibodies to transducin in a patient with melanoma-associated retinopathy. Am J Ophthalmol 2002; 134:128.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/32\" class=\"nounderline abstract_t\">Bazhin AV, Dalke C, Willner N, et al. Cancer-retina antigens as potential paraneoplastic antigens in melanoma-associated retinopathy. Int J Cancer 2009; 124:140.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/33\" class=\"nounderline abstract_t\">Hartmann TB, Bazhin AV, Schadendorf D, Eichm&uuml;ller SB. SEREX identification of new tumor antigens linked to melanoma-associated retinopathy. Int J Cancer 2005; 114:88.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/34\" class=\"nounderline abstract_t\">Pf&ouml;hler C, Preuss KD, Tilgen W, et al. Mitofilin and titin as target antigens in melanoma-associated retinopathy. Int J Cancer 2007; 120:788.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/35\" class=\"nounderline abstract_t\">Ladewig G, Reinhold U, Thirkill CE, et al. Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV. Br J Dermatol 2005; 152:931.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/36\" class=\"nounderline abstract_t\">Lu Y, Jia L, He S, et al. Melanoma-associated retinopathy: a paraneoplastic autoimmune complication. Arch Ophthalmol 2009; 127:1572.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/37\" class=\"nounderline abstract_t\">Berson EL, Lessell S. Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol 1988; 106:307.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/38\" class=\"nounderline abstract_t\">Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 2001; 21:173.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/39\" class=\"nounderline abstract_t\">Subhadra C, Dudek AZ, Rath PP, Lee MS. Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuroophthalmol 2008; 28:23.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/40\" class=\"nounderline abstract_t\">Jacobzone C, Cochard-Marianowski C, Kupfer I, et al. Corticosteroid treatment for melanoma-associated retinopathy: effect on visual acuity and electrophysiologic findings. Arch Dermatol 2004; 140:1258.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/41\" class=\"nounderline abstract_t\">Chan C, O'Day J. Melanoma-associated retinopathy: does autoimmunity prolong survival? Clin Exp Ophthalmol 2001; 29:235.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/42\" class=\"nounderline abstract_t\">Pillay N, Gilbert JJ, Ebers GC, Brown JD. Internuclear ophthalmoplegia and &quot;optic neuritis&quot;: paraneoplastic effects of bronchial carcinoma. Neurology 1984; 34:788.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/43\" class=\"nounderline abstract_t\">Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49:146.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/44\" class=\"nounderline abstract_t\">Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54:38.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/45\" class=\"nounderline abstract_t\">Ducray F, Roos-Weil R, Garcia PY, et al. Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2007; 78:325.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/46\" class=\"nounderline abstract_t\">Moss HE, Liu GT, Dalmau J. Glazed (vision) and confused. Surv Ophthalmol 2010; 55:169.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/47\" class=\"nounderline abstract_t\">de la Sayette V, Bertran F, Honnorat J, et al. Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol 1998; 55:405.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/48\" class=\"nounderline abstract_t\">Sheorajpanday R, Slabbynck H, Van De Sompel W, et al. Small cell lung carcinoma presenting as collapsin response-mediating protein (CRMP) -5 paraneoplastic optic neuropathy. J Neuroophthalmol 2006; 26:168.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/49\" class=\"nounderline abstract_t\">Thambisetty MR, Scherzer CR, Yu Z, et al. Paraneoplastic optic neuropathy and cerebellar ataxia with small cell carcinoma of the lung. J Neuroophthalmol 2001; 21:164.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/50\" class=\"nounderline abstract_t\">Malik S, Furlan AJ, Sweeney PJ, et al. Optic neuropathy: a rare paraneoplastic syndrome. J Clin Neuroophthalmol 1992; 12:137.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/51\" class=\"nounderline abstract_t\">Luiz JE, Lee AG, Keltner JL, et al. Paraneoplastic optic neuropathy and autoantibody production in small-cell carcinoma of the lung. J Neuroophthalmol 1998; 18:178.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/52\" class=\"nounderline abstract_t\">Boghen D, Sebag M, Michaud J. Paraneoplastic optic neuritis and encephalomyelitis. Report of a case. Arch Neurol 1988; 45:353.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/53\" class=\"nounderline abstract_t\">Pulido J, Cross SA, Lennon VA, et al. Bilateral autoimmune optic neuritis and vitreitis related to CRMP-5-IgG: intravitreal triamcinolone acetonide therapy of four eyes. Eye (Lond) 2008; 22:1191.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/54\" class=\"nounderline abstract_t\">Ar&eacute;s-Luque A, Garc&iacute;a-Tu&ntilde;&oacute;n LA, Saiz A, et al. Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies. J Neurol 2007; 254:1131.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/55\" class=\"nounderline abstract_t\">Murakami Y, Yoshida S, Yoshikawa H, et al. CRMP-5-IgG in patient with paraneoplastic optic neuritis with lung adenocarcinoma. Eye (Lond) 2007; 21:860.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/56\" class=\"nounderline abstract_t\">Asproudis IC, Nikas AN, Psilas KG. Paraneoplastic optic neuropathy in a patient with a non-small cell lung carcinoma: a case report. Eur J Ophthalmol 2005; 15:420.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/57\" class=\"nounderline abstract_t\">O'Neal KD, Butnor KJ, Perkinson KR, Proia AD. Bilateral diffuse uveal melanocytic proliferation associated with pancreatic carcinoma: a case report and literature review of this paraneoplastic syndrome. Surv Ophthalmol 2003; 48:613.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/58\" class=\"nounderline abstract_t\">Duong HV, McLean IW, Beahm DE. Bilateral diffuse melanocytic proliferation associated with ovarian carcinoma and metastatic malignant amelanotic melanoma. Am J Ophthalmol 2006; 142:693.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/59\" class=\"nounderline abstract_t\">Saito W, Kase S, Yoshida K, et al. Bilateral diffuse uveal melanocytic proliferation in a patient with cancer-associated retinopathy. Am J Ophthalmol 2005; 140:942.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/60\" class=\"nounderline abstract_t\">Ritland JS, Eide N, Tausj&oslash; J. Bilateral diffuse uveal melanocytic proliferation and uterine cancer. A case report. Acta Ophthalmol Scand 2000; 78:366.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/61\" class=\"nounderline abstract_t\">Kiratli H, Erkan K. Loss of Retinal Pigment Epithelium Associated with Bilateral Diffuse Uveal Melanocytic Proliferation. Ophthalmic Surg Lasers Imaging 2010; :1.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/62\" class=\"nounderline abstract_t\">Besirli CG, Comer GM. High-resolution OCT imaging of RPE degeneration in bilateral diffuse uveal melanocytic proliferation. Ophthalmic Surg Lasers Imaging 2010; 41 Suppl:S96.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/63\" class=\"nounderline abstract_t\">Wu S, Slakter JS, Shields JA, Spaide RF. Cancer-associated nummular loss of the pigment epithelium. Am J Ophthalmol 2005; 139:933.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/64\" class=\"nounderline abstract_t\">Sen J, Clewes AR, Quah SA, et al. Presymptomatic diagnosis of bronchogenic carcinoma associated with bilateral diffuse uveal melanocytic proliferation. Clin Exp Ophthalmol 2006; 34:156.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/65\" class=\"nounderline abstract_t\">Miles SL, Niles RM, Pittock S, et al. A factor found in the IgG fraction of serum of patients with paraneoplastic bilateral diffuse uveal melanocytic proliferation causes proliferation of cultured human melanocytes. Retina 2012; 32:1959.</a></li><li><a href=\"https://www.uptodate.com/contents/paraneoplastic-visual-syndromes/abstract/66\" class=\"nounderline abstract_t\">Jansen JC, Van Calster J, Pulido JS, et al. Early diagnosis and successful treatment of paraneoplastic melanocytic proliferation. Br J Ophthalmol 2015; 99:943.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15837 Version 7.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H2791288\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H2791602\" id=\"outline-link-H2791602\">INTRODUCTION</a></li><li><a href=\"#H2792544\" id=\"outline-link-H2792544\">CANCER-ASSOCIATED RETINOPATHY</a></li><li><a href=\"#H2792551\" id=\"outline-link-H2792551\">MELANOMA-ASSOCIATED RETINOPATHY</a></li><li><a href=\"#H2791281\" id=\"outline-link-H2791281\">OPTIC NEUROPATHY</a></li><li><a href=\"#H4052000\" id=\"outline-link-H4052000\">BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION</a></li><li><a href=\"#H2791288\" id=\"outline-link-H2791288\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"NEURO/15837|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/67930\" class=\"graphic graphic_picture\">- Recoverin and photoreceptors</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-paraneoplastic-syndromes-of-the-nervous-system\" class=\"medical medical_review\">Overview of paraneoplastic syndromes of the nervous system</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=paraneoplastic-and-autoimmune-encephalitis\" class=\"medical medical_review\">Paraneoplastic and autoimmune encephalitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=paraneoplastic-cerebellar-degeneration\" class=\"medical medical_review\">Paraneoplastic cerebellar degeneration</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=paraneoplastic-syndromes-affecting-peripheral-nerve-and-muscle\" class=\"medical medical_review\">Paraneoplastic syndromes affecting peripheral nerve and muscle</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=paraneoplastic-syndromes-affecting-the-spinal-cord-and-dorsal-root-ganglia\" class=\"medical medical_review\">Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia</a></li></ul></div></div>","javascript":null}